Background
A study from Uppsala University details the large-scale clinical validation of a previously described 11-protein diagnostic protein profile for ovarian cancer. Validation analysis was performed by measuring over 1100 clinical samples from two independent cohorts using a custom Olink® panel.
Outcome
This validation study confirmed the performance of the multi-protein model they had identified previously, which in this study showed a sensitivity of 0.83/0.91 and specificity of 0.88/0.92 in the two independent cohorts used. Data-driven modeling of the risk score patterns during a two-year follow-up after diagnosis identified four separate risk score trajectories linked to clinical development and survival. Analysis of 5-year survival showed that at time of diagnosis the risk score is the second-strongest predictive variable for survival after tumor stage.
